Discover Anti-CD66e Recombinant Antibody for Enhanced Research Insights

The anti-CD66e recombinant antibody from Alpha Lifetech Incorporation represents a significant advancement in targeted immunotherapy research. This high-affinity antibody specifically recognizes CD66e, a cell surface glycoProtein implicated in various cancers and immune responses. Engineered using cutting-edge recombinant technology, this antibody offers exceptional specificity and sensitivity, making it an invaluable tool for both diagnostic and therapeutic applications, Alpha Lifetech Incorporation remains committed to providing high-quality reagents that enhance scientific discovery, and the anti-CD66e recombinant antibody is no exception. Unlock new possibilities in your research with this innovative product tailored to meet the highest standards of biomedical investigation

Hot Selling Product

ADT1026-Altumomab Biosimilar (CEACAM5/CD66e)-Research Biosimilar Antibody

ALP64533-Recombinant Mouse Siglec-15 /CD33L3 Protein, His Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

Reasons to Choose anti-cd66e recombinant antibody Global Reach Ahead of the Curve

When it comes to advanced research and therapeutic applications, the choice of reliable reagents is paramount. Among the myriad options available today, the anti-CD66e recombinant antibody from Alpha Lifetech Inc. stands out due to its unparalleled quality and global accessibility. Our commitment to excellence stems from a foundation built by seasoned scientists with extensive expertise in membrane protein production, Nanobody discovery, and monoclonal antibody development. With nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies launched, our portfolio is tailored to meet the diverse needs of researchers and manufacturers worldwide. Choosing the anti-CD66e recombinant antibody means selecting a product that is not just backed by scientific rigor but also adheres to the highest industry standards. Its unique ability to bind specifically to the CD66e antigen makes it an essential tool for various applications, including immunoassays, therapeutic development, and in-depth cellular studies. As researchers and companies seek products that consistently deliver reliable results, our recombinant antibody ensures that you remain ahead of the curve in your scientific endeavors, facilitating innovative breakthroughs in your field. Furthermore, Alpha Lifetech Inc. prides itself on its global reach, offering seamless access to our products regardless of geographical boundaries. Our user-friendly online platform and dedicated customer support service ensure that you can easily procure the anti-CD66e recombinant antibody and other essential reagents. By choosing Alpha Lifetech, you are aligning with a partner who not only provides premium products but also shares your passion for advancing science and improving health outcomes globally.

Reasons to Choose anti-cd66e Recombinant Antibody Global Reach Ahead of the Curve

Feature	Description	Benefit
High Specificity	Designed to target CD66e with minimal cross-reactivity.	Ensures accurate results in diagnostic applications.
Recombinant Technology	Produced using advanced recombinant DNA technology.	Provides high consistency and purity for reliable results.
Global Availability	Readily accessible in various regions worldwide.	Facilitates research and development across borders.
Multipurpose Application	Suitable for various laboratory techniques including ELISA and Western Blotting.	Versatility in research enhances productivity.
Peer-Reviewed Studies	Supported by numerous scientific publications.	Increases confidence in use for critical experiments.

Usage Trends of Recombinant Antibodies in Research and Development

This line chart illustrates the increasing trend in the usage of recombinant antibodies across research and development from 2018 to 2023. Starting from a usage of 1500 units in 2018, there has been a significant growth each subsequent year, culminating in approximately 7000 units in 2023. The data reflects a growing recognition of the importance of recombinant antibodies in various fields such as immunology, cancer research, and drug development. This upward trajectory may be attributed to advancements in biotechnology that enhance the efficacy and specificity of these antibodies, as well as a broader trend towards personalized medicine where such tools are crucial. This ongoing growth signals an important shift in research methodologies, emphasizing the need for high-quality reagents that can support complex experimental designs and therapeutic strategies.